Constellation Brands: beats consensus and the stock still sinks

Constellation Brands (NYSE: STZ) — the company behind Modelo, Corona and Pacífico in the United States (which imports and markets the Mexican Grupo Modelo brands under license) and wineries such as Robert Mondavi — reported its fiscal second-quarter 2027 results (the quarter ended August 31, 2026) after the market close on Tuesday, October 6, 2026. The numbers beat analyst consensus on both sales and earnings per share. Despite that, the stock dropped nearly 5% in the following session — a "beat but sink" pattern that has now repeated itself several times at this company over the past year and a half.

Context: a stock that has been falling for over a year, for the same reason

Constellation Brands is not an obscure small cap: it is one of the largest publicly traded alcoholic beverage companies in the US and the owner of the country's best-selling beer brand, Modelo Especial, which overtook Bud Light as the number-one beer by volume in the US market back in 2025. But since early 2025 the stock has been in a prolonged decline: by late September 2026 it was trading around $112-116, well below the $170-200 highs it hit little more than a year earlier.

The cause the company itself has repeated quarter after quarter since 2025 is always the same: falling beer consumption among Hispanic consumers in the US, who account for roughly half of Constellation's beer sales. Then-CEO Bill Newlands went as far as explicitly linking that decline to the Trump administration's immigration policy, in remarks reported by NBC News in 2025: according to the company's own internal surveys, around 80% of both Hispanic and non-Hispanic consumers continued to express concern about the socioeconomic environment, with fewer at-home social drinking occasions and fewer store visits out of fear of identity checks. On top of that, tariffs on Mexican imports (Constellation's beer is brewed in Mexico) have added pressure on margins. Ahead of this quarter, Newlands handed the CEO role to Nicholas Fink, who led the October 7 earnings presentation alongside CFO Garth Hankinson.

The concrete, verified numbers

Per the 10-Q filed with the SEC and the October 6, 2026 earnings release:

• Consolidated net sales: $2,633.0 million, up 6% from $2,481.0 million in the same quarter a year earlier, and above analyst consensus (around $2.57 billion).
• Beer segment net sales (90%+ of the total): $2,473.6 million versus $2,345.0 million a year earlier.
• Comparable earnings per share: $3.74, versus $3.63 in the same quarter a year earlier and above consensus (around $3.62).
• Net income attributable to the company: $565.8 million, versus $466.0 million a year earlier (+21%), helped by lower taxes and shipment volume growth, partly offset by an asset impairment charge and higher marketing spend.
• Updated guidance: the company raised its reported (GAAP) EPS outlook for fiscal 2027 to a range of $11.85-$12.55, and reaffirmed its comparable EPS outlook of $11.20-$11.90.

Here is how comparable EPS has moved quarter by quarter over the past year and a half — note the strong seasonality (the summer quarter, which includes July and August, is consistently the strongest) and the scale of the winter-quarter (Feb 2026) slump:

The problem is not in these aggregate figures but in the detail that actually moves the stock: "depletions" (the metric the beer industry and the market watch closely, tracking shipments from distributor to retail point of sale) of the two flagship brands fell again. Modelo Especial declined by roughly 2% and Corona Extra by around 5%, with total group beer depletions at -0.6% versus a market expectation of a flat to slightly positive number. The stock, which had closed the October 6 session up 2% at $115.67 ahead of the results, opened on October 7 down to around $109.99 — a drop of nearly 5% that pushed it below its new 52-week low, in a session where the broader market traded normally. To put the scale of the cumulative decline in context: on September 28, just days before the report, the stock was already trading at $112.77, against an average analyst price target of $165 (with the highest estimate at $223 and the lowest at $122) — in other words, the market had already spent months pricing in a deterioration that the quarter's own numbers simply confirmed.

Sector analysis: why this pattern hits different asset types differently

• Consumer staples: Constellation trades within the consumer staples sector, traditionally seen as a safe haven in uncertain environments. This episode is a reminder to investors that "defensive" does not mean immune to idiosyncratic shocks — here, a demand shock concentrated in one very specific demographic segment (Hispanic consumers) and amplified by immigration and tariff policy, not by the broader economic cycle.
• Beer and beverage peers (Molson Coors, Boston Beer, AB InBev): the market tends to watch whether Constellation's weakness is idiosyncratic (tied to its specific exposure to Hispanic consumers and Mexico) or a sign of a broader slowdown in away-from-home alcohol spending. So far, peer readings have not shown the same concentrated decline, which reinforces the idiosyncratic reading.
• Fixed income / corporate credit: with net income growing strongly (+21%) and cash generation holding to the company's own target (an operating cash flow goal of $2.4-$2.5 billion), Constellation's credit profile has not been threatened by this episode — the drop is purely about future growth perception, not solvency.
• Growth vs. value: paradoxically, the more the stock falls on this recurring issue, the more analysts (Barclays, Morgan Stanley, JPMorgan, UBS, Goldman Sachs, Citi) have kept cutting their price targets throughout 2025 and 2026, turning Constellation into a textbook potential "value trap" for anyone buying purely on a low multiple without first answering the question of when volumes will stabilize.

What to watch next

1. The next monthly/quarterly depletion data for Modelo and Corona: if the volume decline eases below the current -0.6%, it would be the first sign that Hispanic consumer spending is starting to normalize.
2. Developments in immigration and tariff policy toward Mexican goods: any regulatory change on this front (in either direction) would, by the company's own stated thesis, have a direct and fast impact on this consumer segment's appetite.
3. Further price-target revisions following the October 6 report: in the week of the report, the average consensus target was still $165 against a share price of around $110 — a mass downward revision from several research houses would signal Wall Street no longer expects a near-term recovery.
4. The next quarterly report (fiscal Q3 2027), expected in January 2027, which will cover the holiday season — traditionally one of the highest social-consumption periods, and therefore a good test of whether the negative trend holds or eases.

A parallel: this has already happened several times at the same company

The most telling thing about this episode is not that it's new, but that it isn't: in the equivalent fiscal quarter of 2025 (reported that October), the company had already posted an almost identical "volume miss," with then-CEO Bill Newlands speaking of "unprecedented volatility" and "very mixed results" in zip codes with a high Hispanic population. A few months later, in the summer quarter of 2025, the company went as far as cutting its full fiscal-year beer sales guidance (from -4% to -2%). The pattern has repeated for at least four or five consecutive quarters since then: beating consensus on the aggregate numbers but disappointing on volume at the two flagship brands, with the stock reacting negatively every time. For an investor, this suggests the market is no longer pricing "whether" there will be volume weakness, but "when" it reverses — and until there is a clear inflection signal in Modelo and Corona depletions, this "beat but sink" pattern is likely to keep repeating quarter after quarter.